Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Osteopetrosis. Core disease mechanisms, molecular and cellular pathways, i...

This report is retrieval-only and is generated directly from Asta results.

• Papers retrieved: 19
• Snippets retrieved: 20

Relevant Papers

[1] Molecular Mechanisms of Craniofacial and Dental Abnormalities in Osteopetrosis

• Authors: Yu Ma, Ya-Li Xu, Yanli Zhang, X. Duan
• Year: 2023
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/892ca3cdce36f8ff4d5b6e1c76a733568d2bd689
• DOI: 10.3390/ijms241210412
• PMID: 37373559
• PMCID: 10299715
• Citations: 11
• Summary: It is found that all 13 types of osteopetrosis have craniomaxillofacial and dental phenotypes, and it is concluded that the telltale craniof facial and dental abnormalities are important for dentists and other clinicians in the diagnosis of osteOPetrosis and other genetic bone diseases.
• Evidence snippets:
• Snippet 1 (score: 0.510) > Osteopetrosis is a group of genetic bone disorders characterized by increased bone density and defective bone resorption. Osteopetrosis presents a series of clinical manifestations, including craniofacial deformities and dental problems. However, few previous reports have focused on the features of craniofacial and dental problems in osteopetrosis. In this review, we go through the clinical features, types, and related pathogenic genes of osteopetrosis. Then we summarize and describe the characteristics of craniofacial and dental abnormalities in osteopetrosis that have been published in PubMed from 1965 to the present. We found that all 13 types of osteopetrosis have craniomaxillofacial and dental phenotypes. The main pathogenic genes, such as chloride channel 7 gene (CLCN7), T cell immune regulator 1 (TCIRG1), osteopetrosis-associated transmembrane protein 1 (OSTM1), pleckstrin homology domain-containing protein family member 1 (PLEKHM1), and carbonic anhydrase II (CA2), and their molecular mechanisms involved in craniofacial and dental phenotypes, are discussed. We conclude that the telltale craniofacial and dental abnormalities are important for dentists and other clinicians in the diagnosis of osteopetrosis and other genetic bone diseases.

[2] Clinical, genetic aspects and molecular pathogenesis of osteopetrosis

• Authors: D. Nadyrshina, R. Khusainova
• Year: 2023
• Venue: Vavilov Journal of Genetics and Breeding
• URL: https://www.semanticscholar.org/paper/363334bbbc470c136915249d0e92bc581ecccb7a
• DOI: 10.18699/VJGB-23-46
• PMID: 37465191
• PMCID: 10350861
• Citations: 7
• Influential citations: 1
• Summary: The current state of the art in this field, including clinical and genetic aspects, and the molecular pathogenesis of the osteopetrosis are summarized.
• Evidence snippets:
• Snippet 1 (score: 0.406) > Clinical, genetic aspects and molecular pathogenesis of osteopetrosis
• Snippet 2 (score: 0.402) > Osteopetrosis is a clinically and genetically heterogeneous group of disorders the diagnosis of which is complicated by the presence of different clinical forms and types of inheritance and the absence of a clear correlation between genotype and phenotype. Moreover, the mutations identified to date explain only 70 % of cases of osteopetrosis. The search for the molecular defects responsible for the remaining 30 % of the disease continues. > The study of osteopetrosis is necessary for DNA diagnosis, treatment prescription, and prognosis. The study of os teopetrosis has shed light on little-known aspects of bone tissue cell biology and identified new mechanisms of osteoclast differentiation and function.

[3] Organoids in gastrointestinal diseases: from bench to clinic

• Authors: Qinying Wang, Fanying Guo, Qinyuan Zhang, Tingting Hu, Yutao Jin et al.
• Year: 2024
• Venue: MedComm
• URL: https://www.semanticscholar.org/paper/9b8880d8b9d45670da950197d7e353794f51d09e
• DOI: 10.1002/mco2.574
• PMID: 38948115
• PMCID: 11214594
• Citations: 12
• Summary: A comprehensive and systematical depiction of organoids models is drawn, providing a novel insight into the utilization of organoids models from bench to clinic and clinical adhibition.
• Evidence snippets:
• Snippet 1 (score: 0.405) > Organoids models offer a robust platform for investigating the potential mechanisms of GI diseases and evaluating potential therapeutic interventions.By culturing organoids derived from patients' tissues or stem cells, researchers can delve into disease-specific cellular and molecular pathways, encompassing aberrant cell signaling, perturbed immune responses, and dysfunctional metabolic processes.These disease-specific phenotypes enable the study of disease progression, screening of prospective therapeutics, as well as identification of novel drug targets and mechanisms of action for GI diseases in a clinically relevant context.

[4] New therapeutic targets in rare genetic skeletal diseases

• Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
• Year: 2015
• Venue: Expert Opinion on Orphan Drugs
• URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
• DOI: 10.1517/21678707.2015.1083853
• PMID: 26635999
• PMCID: 4643203
• Citations: 37
• Influential citations: 1
• Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
• Evidence snippets:
• Snippet 1 (score: 0.404) > proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[5] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

• Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
• Year: 2025
• Venue: Journal of Veterinary Internal Medicine
• URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
• DOI: 10.1111/jvim.70139
• PMID: 40492724
• PMCID: 12150350
• Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
• Evidence snippets:
• Snippet 1 (score: 0.396) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[6] Osteopetrosis: classification, pathomorphology, genetic disorders, clinical manifestations (literature review and clinical case report)

• Authors: V. Povoroznyuk, N. Dedukh, M. Bystrytska, A. Musiienko
• Year: 2019
• Venue: PAIN. JOINTS. SPINE
• URL: https://www.semanticscholar.org/paper/94ef09cd3e2d2d3ea69b144f9925736d062ade1d
• DOI: 10.22141/2224-1507.9.2.2019.172125
• Citations: 3
• Summary: The paper presents with clinical case report of a patient with marble bone disease and the main pathomorphological changes in the structural organization of bone tissue are presented and features of the state of osteoclasts are shown depending on the mutation of genes controlling their functional activity.
• Evidence snippets:
• Snippet 1 (score: 0.395) > Osteopetrosis: classification, pathomorphology, genetic disorders, clinical manifestations (literature review and clinical case report)

[7] Intramedullary Canal-creation Technique for Patients with Osteopetrosis

• Authors: J. Kent, D. Ferguson
• Year: 2020
• Venue: Strategies in Trauma and Limb Reconstruction
• URL: https://www.semanticscholar.org/paper/438a0b7172b6e8202c22c9941d251bbd31c3d481
• DOI: 10.5005/jp-journals-10080-1424
• PMID: 32742432
• PMCID: 7368361
• Citations: 2
• Summary: Fractures and nonunions in patients with osteopetrosis are difficult to manage; and by detailing this technique, a further option is now available for surgeons when deciding upon fixation method.
• Evidence snippets:
• Snippet 1 (score: 0.395) > Osteopetrosis is a rare, hereditary condition characterised by hard, brittle, "marble bone" primarily due to osteoclast dysfunction. > The incidence is 1 in 100,000 to 500,000, 1,2 and it occurs in three main forms, namely, infantile, intermediate, and adult onset. These differ by their genetic inheritance and subsequent clinical findings. 3 Infantile is autosomal recessive (AR) and results in bone marrow failure and a significantly decreased life expectancy unless bone marrow transplant is successfully performed. Intermediate is also due to AR inheritance, whereas adult onset has an autosomal dominant pattern and forms a spectrum of severity and clinical findings, including specific orthopaedic manifestations. > The primary underlying defect in all types of osteopetrosis is failure of bone reabsorption. This can occur due to a defect within the osteoclast lineage resulting in decreased acid secretion or osteoclast maturation or with the mesenchymal cells necessary for their correct function. Multiple genes have thus been implicated and there is also evidence of not only osteoclast involvement but also osteoblasts. 4 ysfunctional osteoclast activity is predominantly due to defective chloride channel 7 (ClCN7) and T cell immune regulator 1 (TCIRG1) (116 kD subunit of vacuolar proton pump) genes. 5 hese result in impairment of acidification due to defective proton pumps leading to decreased acid secretion and subsequent bone reabsorption. In addition, defects to receptor activating NF-κ B ligand (RANKL) along with monocyte-macrophage-colonystimulating factor (M-CSF) genes are responsible for inhibiting the maturation of functional, osteoclast formation. 4 Due to the clinical spectrum seen, additional genetic and environmental determinants affecting gene penetrance have also been implicated. > Other specific forms also exist, which are characterised by renal tubular acidosis and cerebral calcification due to carbonic anhydrase isoenzyme II deficiency, which again results in decreased acid secretion, 6 and due to cathepsin K mutation resulting in pycnodysostosis. 7

[8] Molecular and clinical heterogeneity in CLCN7‐dependent osteopetrosis: report of 20 novel mutations

• Authors: A. Pangrazio, M. Pusch, E. Caldana, A. Frattini, E. Lanino et al.
• Year: 2010
• Venue: Human Mutation
• URL: https://www.semanticscholar.org/paper/24317e48a583ed2e72271145f7b06fe24494fd94
• DOI: 10.1002/humu.21167
• PMID: 19953639
• Citations: 88
• Influential citations: 5
• Summary: Preliminary genotype‐phenotype correlations suggest that haploinsufficiency is not the mechanism causing ADO II, and the availability of biochemical assays to characterize ClC‐7 function will help to confirm this hypothesis.
• Evidence snippets:
• Snippet 1 (score: 0.388) > The “Osteopetroses” are genetic diseases whose clinical picture is caused by a defect in bone resorption by osteoclasts. Three main forms can be distinguished on the basis of severity, age of onset and means of inheritance: the dominant benign, the intermediate and the recessive severe form. While several genes have been involved in the pathogenesis of the different types of osteopetroses, the CLCN7 gene has drawn the attention of many researchers, as mutations within this gene are associated with very different phenotypes. We report here the characterization of 25 unpublished patients which has resulted in the identification of 20 novel mutations, including 11 missense mutations, 6 causing premature termination, 1 small deletion and 2 putative splice site defects. Careful analysis of clinical and molecular data led us to several conclusions. First, intermediate osteopetrosis is not homogeneous, since it can comprise both severe dominant forms with an early onset and recessive ones without central nervous system involvement. Second, the appropriateness of haematopoietic stem cell transplantation in CLCN7‐dependent ARO patients has to be carefully evaluated and exhaustive CNS examination is strongly suggested, as transplantation can almost completely cure the disease in situations where no primary neurological symptoms are present. Finally, the analysis of this largest cohort of CLCN7‐dependent ARO patients together with some ADO II families allowed us to draw preliminary genotype‐phenotype correlations suggesting that haploinsufficiency is not the mechanism causing ADO II. The availability of biochemical assays to characterize ClC‐7 function will help to confirm this hypothesis. © 2009 Wiley‐Liss, Inc.

[9] Identification of the first deletion in the LRP5 gene in a patient with Autosomal Dominant Osteopetrosis type I

• Authors: A. Pangrazio, E. Boudin, E. Piters, G. Damante, N. L. Iacono et al.
• Year: 2011
• Venue: Bone
• URL: https://www.semanticscholar.org/paper/f885e59dcea94368989f9c1e4b66a13d40acf790
• DOI: 10.1016/j.bone.2011.05.006
• PMID: 21600326
• PMCID: 3149657
• Citations: 33
• Summary: A patient who presented with a clinical picture of Autosomal Dominant Osteopetrosis type I (ADO I), in whom the first deletion in the LRP5 gene causing increased bone mass was identified, highlighting an increasing molecular heterogeneity in L RP5-related bone diseases.
• Evidence snippets:
• Snippet 1 (score: 0.387) > At the end of the eighties, Bollerslev and Andersen reviewed a large group of patients affected by Autosomal Dominant Osteopetrosis (ADO) and, on the basis of radiological and biochemical findings, suggested that two different types of ADO existed [1].More recently this clinical observation was supported by the results of molecular investigations in patients, which showed that monoallelic defects in low-density lipoprotein receptor-related protein 5 (LRP5) gene caused human ADO I, in which the long bones and the skull are mainly affected, while mutations in a single allele of the chloride channel 7 (ClCN7) gene were responsible for ADO II, in which an increased rate of bone fractures is reported.Both LRP5 and ClCN7 proteins are involved in signalling pathways or cellular processes which are crucial in bone metabolism as demonstrated by the range of bone diseases arising from different mutations in either encoding gene.In particular, biallelic loss of function mutations in LRP5 are responsible for the autosomal recessive osteoporosis pseudoglioma syndrome (OPPG; MIM 259770) [2][3][4]; on the contrary, monoallelic mutations in LRP5, initially thought to lead to a gain of function of the protein product, cause a range of phenotypes inherited in an autosomal dominant way and characterised by increased bone density.These are endosteal hyperostosis (MIM 144750), osteosclerosis (MIM 144750), dominant osteopetrosis (MIM 607634), van Buchem disease type 2 (VBCH2; MIM 607636) and high bone mass syndrome (HBM; MIM 601884) [4][5][6][7][8][9].In addition, studies in different populations have suggested that LRP5 could be a susceptibility gene for osteoporosis and fracture risk [10,11]. > The specific clinical picture is strongly related to the LRP5 domain affected by the mutation.

[10] Osteoclast Genetic Diseases

• Authors: A. D. Fattore, A. Teti
• Year: 2011
• Venue: Unknown venue
• URL: https://www.semanticscholar.org/paper/ac91c528442ed639bbef3343b3cb29cc2ea3cb6b
• DOI: 10.5772/23417
• Citations: 4
• Summary: Often osteoclast diseases are monogenic, and in many of them the responsible gene and the respective function have been identified, while for other osteopetrosis, pycnodysostosis and Paget's disease of bone the causative gene has not been isolated or the exact function of the matching protein still remains unknown.
• Evidence snippets:
• Snippet 1 (score: 0.383) > Osteopetrosis is a rare (>1:100.000)genetic disorder characterized by an impaired osteoclast function that leads to pathological increase of bone mass and skeletal fragility.It was identified for the first time in 1904 by Albers-Scönberg, who described a patient with generalized sclerosis of the skeleton, suffering from several fractures (Albers-Schönberg, 1904).Subsequently, in 1926, Karshner denominated the syndrome "marble bone disease" or "osteopetrosis" (Karshner, 1926).Impaired bone resorption causes persistence of old bone, increase of bone mass and obstruction of cavities containing vital organs such as the bone marrow and the nervous system.Osteopetrotic patients usually suffer from pathological fractures, short stature and haematological and neural failures (Balemans et al.;2005;Del Fattore et., 2008;Frattini et.;2003;Loria-Cortes et al., 1977).Osteopetrosis is a heterogeneous disorder which includes several forms that differ on the basis of inheritance, severity and secondary clinical features (Balemans et al., 2005).So far, there is no effective cure for osteopetrosis (Del Fattore et al., 2010).Haematopoietic Stem Cell Transplantation (HSCT) is indicated only for some severe forms; however a large rate of unsuccessful engraftment and persistence of irreversible symptoms are frequently observed (Driesses et al., 2003).

[11] Zebrafish Models for Human Skeletal Disorders

• Authors: M. Marí-Beffa, Ana B. Mesa-Román, Ivan Duran
• Year: 2021
• Venue: Frontiers in Genetics
• URL: https://www.semanticscholar.org/paper/965c289599ff2b38e8ba04136ce390d3cacd7356
• DOI: 10.3389/fgene.2021.675331
• PMID: 34490030
• PMCID: 8418114
• Citations: 29
• Summary: This article reviews the state-of-art of this “aquarium to bedside” approach describing the models according to the list provided by the Nosology Committee and intends to stimulate research in the appropriate direction to efficiently meet the actual needs of clinicians.
• Evidence snippets:
• Snippet 1 (score: 0.380) > Skeletal disorders are a heterogeneous group of rare hereditary diseases with many different skeletal symptoms and molecular mechanisms of disease (Krakow and Rimoin, 2010). These diseases are characterized by skeletal defects that appear during development and/or growth, the dysplasia, or at late stages and/or adulthood. These disorders may also show symptoms in other organs. Although skeletal disorders are considered rare diseases, they affect around 1.5% of births and emerge as a primary scientific objective in modern countries. Due to the available data that arise from whole genome (Wheway et al., 2015) or exome (Bamshad et al., 2011) sequencing of patients and genomewide association studies (GWASs) (Kemp et al., 2017), sufficient information is being screened for the genotype/phenotype characterization of many of these diseases. > During the last 50 years, these disorders have been subjected to a continuous revision by a Nosology Committee of the International Skeletal Dysplasia Society. This committee periodically provides a classification of them according to anatomical or physiological symptoms and genomic data, the Nosology and Classification of Genetic Skeletal Disorders (NCGSD). In the last version (Mortier et al., 2019), 461 skeletal diseases were classified in 42 groups, and 437 genes were assigned as causative of 425 of them. The anatomical features used to classify these diseases range from the tissue (chondrodysplasia or osteodysplasia) or cell affected (i.e., osteoclasts dysfunction in osteopetrosis), the severity of phenotype (achondroplasia vs. hypochondroplasia), specific genotype/phenotype relationships (FGFR3 chondrodysplasia and collagenopathies), cell functions affected (i.e., ciliopathies or cohesinopathies), or even the specific cell pathologies involved (i.e., ER-cell stress). In the NCGSD-2019, single pathogenic gene variants may be associated with several disease groups, and various phenotypes in turn may be assigned to more than one gene mutation.

[12] Clinical and Radiological Findings of Autosomal Dominant Osteopetrosis Type II: A Case Report

• Authors: P. Kant, N. Sharda, R. Bhowate
• Year: 2013
• Venue: Case Reports in Dentistry
• URL: https://www.semanticscholar.org/paper/12e1ce3d699dee9f05c9997505a68aa245960ed6
• DOI: 10.1155/2013/707343
• PMID: 24260721
• PMCID: 3821930
• Citations: 17
• Influential citations: 1
• Summary: The clinical and radiographic features of a 35-year-old female patient with autosomal dominant osteopetrosis type II who exhibited features of chronic generalised periodontitis, and the radiographs revealed generalised osteosclerosis and hallmark radiography features of ADO type II, that is, “bone-within-bone appearance” and “Erlenmeyer-flask deformity.”
• Evidence snippets:
• Snippet 1 (score: 0.380) > The term osteopetrosis is derived from the Greek word "osteo" meaning bone and "petros" meaning stone. Osteopetrosis is referred to as "marble bone disease" and "Albers-Schönberg disease", after the German radiologist credited with the first description of the condition in 1904 [1]. Osteopetrosis comprises a clinically and genetically heterogeneous group of conditions that share the hallmark of increased bone density on radiographs. The increase in bone density results from abnormalities in osteoclast differentiation or function [2]. In healthy bone, a steady state is achieved in which production of bone by cells called osteoblasts is balanced by bone resorption by osteoclasts. Dysfunctional osteoclasts that are observed in osteopetrosis result in bony overgrowth, leading to bones that are abnormally dense and brittle. It is believed that osteoclasts fail to release the necessary lysosomal enzymes for bone resorption into the extracellular space [3,4]. > Defects in different genes have been described that lead to a phenotype with osteopetrosis, and mutations in at least 10 genes have been identified as causative in humans. These defects include mutations in the gene encoding carbonic anhydrase II, the proton pump gene, and the chloride channel gene [5,6]. Recently, the immune response has been incriminated in the pathogenesis of various metabolic bone diseases, including osteopetrosis. Both cytotoxic T lymphocyte-associated antigen 4 and programmed death-1, a newly identified immunoregulatory receptor, have been shown to negatively regulate immune responses and to affect osteoclastogenesis and bone remodeling [7]. > This disease has been reported in three clinical forms: (1) malignant infantile form with poor prognosis and autosomal recessive inheritance, (2) benign/adult osteopetrosis with autosomal dominant inheritance and with fewer symptoms, (3) autosomal recessive intermediate form with clinical manifestations similar to malignant form and lowest incidence rate [8][9][10].

[13] TNF receptor-associated factors: promising targets of natural products for the treatment of osteoporosis

• Authors: Xicheng Yang, Lili Zhao, YinQuan Pang
• Year: 2025
• Venue: Frontiers in Physiology
• URL: https://www.semanticscholar.org/paper/d9021ed6a69cee708a998f67bb9fb923ec06671b
• DOI: 10.3389/fphys.2025.1527814
• PMID: 40496246
• PMCID: 12148923
• Citations: 2
• Summary: The mechanisms by which natural compounds modulate TRAF signaling in osteoclastogenesis and osteoblastogenesis are explored, providing insights into their potential for osteoporosis treatment.
• Evidence snippets:
• Snippet 1 (score: 0.380) > Understanding the intricacies of these cellular and molecular mechanisms is crucial for unraveling the pathophysiology of bone disorders like osteoporosis and developing targeted therapeutic interventions to mitigate their impact. Yang et al. 10.3389/fphys.2025.1527814 3 Pathophysiology of osteoporosis > Osteoporosis is a complex skeletal disorder indicative of reduced BMD and deterioration of bone microarchitecture, causing enhanced bone fragility and susceptibility to fractures. The pathophysiology of osteoporosis involves a disruption in the delicate balance between osteoclastic bone resorption and osteoblastic bone formation within the process of bone remodeling.

[14] Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review

• Authors: Haidi Bi, Xing Chen, Song Gao, Xiao-Long Yu, Jun Xiao et al.
• Year: 2017
• Venue: Frontiers in Medicine
• URL: https://www.semanticscholar.org/paper/e47a465d11867900c3c32555435e8795987deb20
• DOI: 10.3389/fmed.2017.00234
• PMID: 29326938
• PMCID: 5742334
• Citations: 126
• Influential citations: 2
• Summary: The aim of this review is to provide an updated summary of the current progress in research involving osteoclast-related diseases and of the development of targeted inhibitors of osteOClast formation.
• Evidence snippets:
• Snippet 1 (score: 0.376) > Osteopetrosis is a metabolic bone disease characterized by increased bone mass caused by polygenic disorders. Disorders in osteoclast formation and loss of osteoclast function are the main reasons for decreased bone resorption and increased bone mass. Recent studies have suggested that decreased bone resorption could be caused by abnormalities in the RANKL/RANK/OPG system, lack of c-Fos protein, and mutations in M-CSF, while mutations in the vacuolar (H + )-ATPase (V-ATPase) subunit, loss of CLC-7 chloride channels, and a shortage of cathepsin K are the most common reasons for osteopetrosis caused by bone resorption disorders. Bone marrow transplantation and the subsequent differentiation of hematopoietic stem cells from the implanted new bone marrow into mature and functioning osteoclasts is a treatment option for osteopetrosis.

[15] “Bridging the Gap” Everything that Could Have Been Avoided If We Had Applied Gender Medicine, Pharmacogenetics and Personalized Medicine in the Gender-Omics and Sex-Omics Era

• Authors: D. Gemmati, K. Varani, B. Bramanti, R. Piva, G. Bonaccorsi et al.
• Year: 2019
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/8b07704baf9c61d095539dcdb4ba800a11209bbb
• DOI: 10.3390/ijms21010296
• PMID: 31906252
• PMCID: 6982247
• Citations: 92
• Influential citations: 3
• Summary: The description and critical discussion of some key selected multidisciplinary topics considered as paradigmatic of sex/gender differences and sex/ gender inequalities will allow to draft and design strategies useful to fill the existing gap and move forward.
• Evidence snippets:
• Snippet 1 (score: 0.365) > A large number of studies have considered pathologies affecting bone, which are numerous and extremely heterogeneous. Bone is a highly dynamic tissue, constantly undergoing to catabolic and anabolic processes to maintain its flexibility and adapt to the demands of the organism for growth, mechanical loading and mineral balance [178]. Bone homeostasis is due to the opposite and complementary action of bone-forming cells (osteoblasts, OBs) and bone-resorbing cells (osteoclasts, OCs). Their synergy is implemented in a functional anatomic structure known as the basic multicellular unit (BMU) [179,180]. A considerable body of literature describes the effects of imbalances in the formation or resorption of bone, which may give rise to various diseases characterized by different levels of bone-remodelling cycle impairment, like osteoporosis, Paget's disease and osteopetrosis [178,181]. The knowledge on the mechanisms underlying the formation and maintenance of bone is rapidly increasing, as well as the development of target therapeutic strategies against bone pathologies and skeletal degeneration [178,182,183]. However, extensive investigations are hampered by the limited accessibility of bone tissue, its mineralized nature, as well as by the complexity of the molecular aspects of bone turnover processes. As a result, not much work has been done to explore the role of sex/gender in the pathophysiology, diagnosis, prognosis, and treatment of bone diseases. Many critical issues remain open and further research is needed to address emerging new challenges in this field, and to identify relevant therapeutic targets. > Currently, the most relevant approach to this complex thematic considers the numerous variables that may affect the physio-pathological bone microenvironment, namely:

[16] Osteosynthesis of an intertrochanteric fracture on osteopetrosis A case report

• Authors: K. Tabbak, M.A. Kharroube, F. Lamnaouar, C. Elkassimi, A. Rafaoui et al.
• Year: 2024
• Venue: International Journal of Surgery Case Reports
• URL: https://www.semanticscholar.org/paper/731f0b9b3e442ef6a7daa7d78cf68abfc00e50b0
• DOI: 10.1016/j.ijscr.2024.109568
• PMID: 38513419
• PMCID: 10972786
• Summary: Open reduction and anatomic plate fixation remain effective management modalities for trochanteric fractures in osteopetrosis patients as some principles are respected with better consolidation of the osteoporotic fracture.
• Evidence snippets:
• Snippet 1 (score: 0.365) > The name osteopetrosis is derived from the Greek language. 'Osteo' means bone, and 'petrosis' means stone. Therefore, the disease is often referred to colloquially as "marble bone disease." The disease was originally described by a radiologist in Germany, Dr. Albers-Schonberg, in 1904. Bone with abnormally increased density is the key radiographic finding. This increased density is secondary to osteoclast dysfunction and leads to the affected bones being abnormally brittle [4]. > Osteopetrosis is a rare group of bone disorders characterized by osteoclast dysfunction that causes an increase in bone density, impaired remodelling, and thus bone fragility. Intraosteoclast deficiency of the enzyme carbonic anhydrase, as well as at least 10 gene mutations-most importantly, the chloride channel gene CLCN7-have been associated with this disease. Patterns include an autosomal recessive form, osteopetrosis congenita, which carries a poor prognosis with death, usually in infancy. The autosomal dominant form, osteopetrosis tarda, is usually asymptomatic and is found in adults. Malignant variants, known as marble bone disease, are diagnosed in childhood and manifest as recurrent bony fractures, short stature, skull thickening, sensorineural hearing loss, psychomotor retardation, and distal renal tubular acidosis. Bony pain, osteomyelitis, and degenerative joint disease frequently occur [5]. > Healing and fracture remodelling in osteopetrotic patients are unpredictable. The healing response is variable [6]. > The histologic features of bone callus after a traumatic fracture in a patient with osteopetrosis are presented. The fracture callus develops in stages that are apparently normal. The tissue is initially rich in boneforming cells and vessels. One year later, however, unlike mature osteopetrotic bone, the tissue shows no Haversian organization [7]. > Management must be individualized. Decisions on whether to operate, mobilize, and allow normal daily activities must be made on a case-by-case basis, as there are no fixed guidelines for management.

[17] Metabolic bone disorders and the promise of marine osteoactive compounds

• Authors: A. Carletti, P. Gavaia, M. L. Cancela, V. Laizé
• Year: 2023
• Venue: Cellular and Molecular Life Sciences: CMLS
• URL: https://www.semanticscholar.org/paper/e71c875a4a92972d503f33ab03044e3d3db6181e
• DOI: 10.1007/s00018-023-05033-x
• PMID: 38117357
• PMCID: 10733242
• Citations: 14
• Summary: The marine osteoactive compounds currently identified and spotted the groups of marine organisms with potential for MOC production are inventoried and the availability of in vivo screening and validation tools for the study of MOCs are briefly examined.
• Evidence snippets:
• Snippet 1 (score: 0.365) > These pathologies are characterized by a vast group of rare, primary monogenic disorders gathered under the name osteopetrosis, also known as the marble bone disease. Osteopetrosis is characterized by a defective bone resorption, increased bone mass and high BMD, and is associated with bone fragility and an increased risk of fractures, and, in some cases, with defective bone marrow, kidney, and nervous and immune systems [50]. There are two prevalent forms of osteopetrosis, which are distinguishable based on their inheritance modality. A more prevalent, milder, and typically late-onset form (arising late during childhood) known as autosomal dominant osteopetrosis (ADO), and a more rare, aggressive and early-onset form (arising early after birth) associated with severe phenotypes and poor prognosis, known as autosomal recessive osteopetrosis (ARO) [50]. ARO can be subdivided into osteoclast-poor and osteoclast-rich forms, depending on whether the mutation at the origin of the disease affects a gene linked to osteoclast differentiation or resorptive function [50]. In addition, a rare form of X-linked osteopetrosis (XLO) has also been described [51]. > Mutations in genes that are central to osteoclast function have been associated with the etiology of osteopetrosis, in particular those involved in the acidification of bone microenvironment (TCIRG1, CNCL7), degradation of the extracellular matrix (CTSK), and cell differentiation (RANK, RANKL, CSF1R, NEMO, RELA) [52]. There are currently no pharmaceutics to efficiently treat osteopetrosis, and therapeutic approaches are only aimed at managing symptoms and relieve pain, e.g., supplementation of vitamin D and calcium in patients with hypercalcemic seizures, transfusion of red blood cells and platelets in patients with bone marrow failure, transplantation of hematopoietic stem cells in patient suffering from the most severe forms of osteopetrosis [50]. > What is on the menu?

[18] Exocrine Pancreatic Dysfunction in Diabetes: An Observational Study

• Authors: Ipsita Ghosh, M. Basu, Beatrice Anne, P. Mukhopadhyay, Sujoy Ghosh
• Year: 2021
• Venue: Indian Journal of Endocrinology and Metabolism
• URL: https://www.semanticscholar.org/paper/a9b7ca8756816322c0ff72ee6d085c2237512950
• DOI: 10.4103/ijem.IJEM_822_20
• PMID: 34386397
• PMCID: 8323623
• Citations: 2
• Summary: The pancreatic enzyme replacement therapy (PERT) with mixed meals to evaluate changes in glycemic state have yielded variable results.
• Evidence snippets:
• Snippet 1 (score: 0.365) > Osteopetrosis (Marble bone disease or Albers-Schönberg disease or Osteitis Condensans Generalisata) is a rare heterogeneous group of metabolic bone disease in which there is impaired osteoclastic function of bone resorption resulting sclerotic bones. Osteopetrosis is categorized by clinical severity and inheritance pattern into milder or benign autosomal dominant form of adult to severe or malignant, autosomal recessive form of infants, and autosomal recessive intermediate form. [1] There is defect in acidification of bones in osteopetrosis due to three mutations. First, the most common is defect in the A3 subunit of the osteoclast vacular H+-ATPase proton pump and the two other are CLCN7 and carbonic anhydrase II defect. [2] The excessive osseous tissue in sclerotic bones compromise marrow spaces, that is responsible for cytopenias and extramedullary hematopoiesis. Anemia in osteopetrosis is leukoerythroblastic in type. Constricted cranial foraminas leads to multiple cranial nerve palsies. Rickets is a paradoxical complication of infantile osteopetrosis because of impaired osteoclastic function to maintain normal calcium phosphorus balance in extra cellular fluid, despite markedly total positive calcium balance as majority of total body calcium is sequestrated in skeleton tissue. This fall in calcium is further exacerbated by inadequate dietary intake of calcium or poor absorption from gastrointestinal tract. Persistence hypocalcemia and hypophosphatemia is responsible for decreased mineralization of newly formed chondroid and osteoid bones in osteopetrorickets. [3] motopoietic stem cell transplantation (HSCT) is reserved for severe infantile osteopetrosis. It is important to detect and treat underlying rickets in these patients for proper and adequate response of HSCT. Corticosteroids and splenectomy have benefited in some patients with hematological complications but not in all cases. The host osteoclasts cells can be stimulated

[19] Genetics and Epigenetics of Bone Remodeling and Metabolic Bone Diseases

• Authors: L. Otòn-Gonzalez, C. Mazziotta, M. Iaquinta, E. Mazzoni, Riccardo Nocini et al.
• Year: 2022
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/eba8f239e766b5289526ae96336548df534f650a
• DOI: 10.3390/ijms23031500
• PMID: 35163424
• PMCID: 8836080
• Citations: 65
• Influential citations: 5
• Summary: The genetics and epigenetics of the bone remodeling process are summarized and described and the current findings behind the genetics of metabolic bone diseases are reported.
• Evidence snippets:
• Snippet 1 (score: 0.361) > Osteopetrosis, also known as Marble bone disease or Albers-Schönberg disease, is a rare genetic, heritable condition that causes increased bone density [45]. Osteopetrosis may be caused by mutations in at least 10 genes. Genetically and clinically, osteopetrosis is very heterogeneous, therefore, accurate molecular classification is relevant for prognosis and treatment [196]. The disease progresses as the bones grow; the cavities of the marrow are filled with compact bone which results in a reduced amount of marrow, which in turn reduces the bone's capacity to produce red blood cells. This can lead to severe anemia. Three forms of osteopetrosis can be distinguished based on the pattern of inheritance: (i) autosomal recessive, (ii) autosomal dominant, and (iii) X-linked. The first, which accounts for the most severe forms, is caused by biallelic mutations in TCIRG1, CLCN7, OSTM1, SNX10, and PLEKHM1 genes, encoding for proteins involved in the acidification of the resorption lacunae and/or in vesicular transport and loss-of-function mutations leading to osteoclast-rich osteopetrosis. Furthermore, mutations in RANKL and its receptor RANK are associated with osteoclast-poor autosomal recessive, where osteoclastogenesis is blocked [197,198]. The second osteopetrosis form can be type I or II; both differ in the presentation of clinical features and genetic mutations located in the LRP5 and CLCN7 genes, respectively. Type I derives from enhanced osteoblast activity due to reduced LRP5 affinity for the extracellular antagonists SOST and dikkopf-1 (DKK-1) and consequent increased Wnt canonical signaling [199], while the most common cause of type 2 is the presence of inactivating mutations in the chloride channel 7 (CLCN7) gene, which results in ineffective, osteoclast-mediated bone resorption [200].

Notes

• This provider combines search_papers_by_relevance with snippet_search.
• No synthesis or second-stage model call is performed.

1. Core Pathophysiology

Osteopetrosis (marble bone disease) is a group of genetic bone disorders characterized by defective osteoclast-mediated bone resorption, leading to abnormally dense, sclerotic bones (pmc.ncbi.nlm.nih.gov). Under normal physiology, continuous bone remodeling maintains skeletal integrity through a balance of bone formation by osteoblasts and bone resorption by osteoclasts (pmc.ncbi.nlm.nih.gov). In osteopetrosis this balance is disrupted: osteoclast function or development is impaired, causing bone to accumulate without proper remodeling (pmc.ncbi.nlm.nih.gov). The primary mechanism is failure of osteoclasts to resorb bone, due either to insufficient osteoclast numbers or dysfunctional osteoclast activity (www.ncbi.nlm.nih.gov). Without normal resorption, bone tissue becomes overly mineralized and “stone-like” (osteosclerosis), yet paradoxically brittle, since old bone is not replaced by new bone (www.ncbi.nlm.nih.gov). The resorption defect originates from molecular abnormalities in osteoclasts – for example, inability to acidify the extracellular resorption lacuna or to adhere to and degrade the bone matrix. Consequently, patients develop generalized high bone mass with occluded marrow cavities and abnormal bone microarchitecture, which underlies the clinical manifestations (pmc.ncbi.nlm.nih.gov). Key downstream effects include a tendency to pathological fractures despite increased bone density and bone marrow failure due to marrow space obliteration (pmc.ncbi.nlm.nih.gov). In severe forms, there is extramedullary hematopoiesis (enlarged liver and spleen) and cranial nerve compression from narrowed skull foramina (pmc.ncbi.nlm.nih.gov). In summary, osteopetrosis represents a failure of normal bone turnover caused by inherited defects in osteoclasts, resulting in accumulation of dense but fragile bone and multi-system complications.

Mechanistically, osteoclasts are unable to erode bone. Osteoclasts normally secrete protons and proteases into a sealed resorption lacuna to dissolve mineral (hydroxyapatite) and digest collagen. In osteopetrosis, this process is subverted by genetic mutations that impede key steps: proton pump function, chloride transport, acid production, vesicular trafficking, cytoskeletal organization, or cell differentiation (detailed below). As a result, bone resorption is markedly reduced or absent, while osteoblasts continue to lay down new bone, tilting the formation/resorption balance. Over time, this leads to persistent calcified cartilage and primary bone (which should have been removed during growth), loss of medullary cavities, and skeletal deformities. For example, failure of fetal osteoclast activity prevents widening of bone marrow spaces, so infants are born with “bone within bone” appearances on X-ray and no proper marrow canal (pmc.ncbi.nlm.nih.gov). The microarchitecture of bone in osteopetrosis is disordered; histology often shows retained calcified cartilage cores and woven bone that is not remodeled into mature lamellar bone (pmc.ncbi.nlm.nih.gov). This explains why bones are brittle – the lack of remodeling means microcracks accumulate and bone tissue is structurally abnormal despite being dense. Thus, the core pathophysiology is an imbalance favoring bone formation over resorption due to osteoclast failure, leading to osteosclerosis with compromised mechanical strength (www.ncbi.nlm.nih.gov). All known subtypes of osteopetrosis trace back to this fundamental mechanism, even though the genetic causes are diverse.

2. Key Molecular Players

Osteopetrosis is genetically heterogeneous, with mutations in at least 10–23 different genes identified as causes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These genes encode proteins crucial for osteoclast development, function, or the bone resorption process. Current understanding (as of 2023) implicates the following major molecular players:

• Osteoclast Acidification Machinery: Osteoclasts must create an acidic microenvironment to dissolve bone mineral. Mutations in genes encoding the proton pump or its regulators are a common cause of osteopetrosis. For instance, TCIRG1 (T-cell immune regulator 1, HGNC:11616) is mutated in ~50% of autosomal recessive osteopetrosis (ARO) cases (pmc.ncbi.nlm.nih.gov). TCIRG1 encodes the a3 subunit of the vacuolar H^+-ATPase proton pump, which is expressed on the osteoclast’s ruffled border membrane and pumps protons into the resorption lacuna (pmc.ncbi.nlm.nih.gov). CLCN7 (HGNC:2059) encodes the chloride channel 7 (ClC-7), a lysosomal Cl^- channel co-localized to the osteoclast ruffled border; it provides charge balance for proton transport and helps maintain the acidic pH (pmc.ncbi.nlm.nih.gov). Mutations in CLCN7 cause both autosomal recessive (severe, “malignant” osteopetrosis) and autosomal dominant (adult benign) osteopetrosis, depending on the allele; dominant-negative CLCN7 mutations underlie the milder Albers-Schönberg disease (ADO type II) (www.ncbi.nlm.nih.gov). OSTM1 (HGNC:16303), encoding osteopetrosis-associated transmembrane protein 1, is an accessory β-subunit that physically complexes with ClC-7 (pmc.ncbi.nlm.nih.gov). Mutations in OSTM1 (accounting for ~5% of ARO) lead to a “neurropathic” variant of osteopetrosis characterized by severe neurodegeneration in addition to bone sclerosis (pmc.ncbi.nlm.nih.gov). OSTM1/ClC-7 defects impair acidification of both the resorption lacuna and lysosomes, arresting bone resorption. Carbonic anhydrase II (gene CA2, HGNC:1387) is another critical component: it generates the intracellular H^+ and HCO_3^- needed for osteoclast acid secretion. Homozygous CA2 mutations cause Type II osteopetrosis (intermediate severity), classically associated with osteopetrosis, renal tubular acidosis, and cerebral calcifications (www.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In all these cases, the molecular pathway of acid production and secretion is disrupted, so osteoclasts cannot dissolve bone mineral. Notably, loss of TCIRG1 or CLCN7 function yields osteoclasts that attach to bone but show no ruffled border formation and little to no resorptive pit activity (pmc.ncbi.nlm.nih.gov). A TCIRG1-deficient osteoclast, for example, cannot pump protons; consequently, hydroxyapatite crystals cannot be dissolved (pmc.ncbi.nlm.nih.gov) and the organic matrix is not degraded, resulting in persistent bone. (As an aside, TCIRG1 is also expressed in gastric parietal cells; patients with TCIRG1 mutations often have impaired stomach acidification and thus hypocalcemia with rickets/osteomalacia due to poor dietary calcium absorption (pmc.ncbi.nlm.nih.gov).)

• Vesicular Trafficking and Bone Degradation: Osteoclasts are highly secretory cells that deploy proton pumps and enzymes to the bone interface via vesicular transport. Genes regulating this membrane trafficking are key players. SNX10 (HGNC:26649, sorting nexin 10) and PLEKHM1 (HGNC:29974) are two genes required for proper vesicle sorting and delivery of osteoclastic enzymes/transporters to the ruffled border (pmc.ncbi.nlm.nih.gov). SNX10, for instance, interacts with the V-ATPase and is needed to traffic the proton pumps to the ruffled border; mutations in SNX10 cause a recessive osteopetrosis first described in Västerbotten, Sweden (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Loss of SNX10 function results in mislocalization of V-ATPase and defective acid secretion (pmc.ncbi.nlm.nih.gov). It may also reduce secretion of matrix metalloprotease-9 (MMP9), an enzyme for collagen degradation in bone, further impairing matrix resorption (pmc.ncbi.nlm.nih.gov). PLEKHM1 encodes a multidomain scaffolding protein important for lysosomal vesicle fusion; PLEKHM1 mutations similarly lead to osteoclasts unable to secrete lysosomal enzymes into the resorption lacuna (pmc.ncbi.nlm.nih.gov). Another gene in this category is CTSK (HGNC:2534), encoding cathepsin K, the chief protease that osteoclasts use to digest collagen and other matrix proteins. Mutations in CTSK cause pycnodysostosis, a form of osteosclerotic dwarfism with brittle bones (pmc.ncbi.nlm.nih.gov). Cathepsin K deficiency demonstrates that even if acid dissolution occurs, failure to degrade the organic matrix can also produce an osteopetrotic phenotype of dense, fracture-prone bone (pmc.ncbi.nlm.nih.gov). Thus, proper targeting of acid and proteases to the bone surface is essential; defects in vesicle trafficking or enzyme function are key molecular mechanisms in osteopetrosis.

• Cellular Differentiation Signals (RANK/RANKL Pathway): A subset of osteopetrosis cases result not from dysfunctional osteoclasts, but from an absence of osteoclasts (“osteoclast-poor” osteopetrosis). These are caused by mutations in factors required for osteoclast lineage differentiation. The most critical pathway here is RANK–RANKL signaling. RANKL (Receptor Activator of NF-κB Ligand, gene TNFSF11, HGNC:11925) is a cytokine produced by osteoblasts and stromal cells that binds RANK on osteoclast precursors to trigger their maturation. RANK (gene TNFRSF11A, HGNC:11916) is the receptor on pre-osteoclasts. Loss-of-function mutations in either can cause human osteopetrosis. About ~2% of ARO cases are due to RANKL deficiency, and ~4–5% due to RANK deficiency (pmc.ncbi.nlm.nih.gov). Without RANKL–RANK interaction, monocyte precursors cannot undergo osteoclast fusion and activation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Consequently, bone biopsies show a complete absence of osteoclasts in these patients (pmc.ncbi.nlm.nih.gov). Clinically, RANKL or RANK mutations lead to severe infantile osteopetrosis, but interestingly RANKL-deficient osteopetrosis tends to have a slightly slower progression than classical malignant ARO (pmc.ncbi.nlm.nih.gov). This may reflect some compensatory bone resorption by RANKL-independent mechanisms or differences in developmental timing. An important difference between these two: osteopetrosis from TNFSF11 (RANKL) mutation cannot be cured by bone marrow transplant, since the defect lies in the non-hematopoietic environment (the patient’s osteoblasts cannot produce RANKL) (pmc.ncbi.nlm.nih.gov). In contrast, TNFRSF11A (RANK) mutations reside in hematopoietic cells, so transplantation can provide donor monocytes with functional RANK and rescue osteoclast formation (pmc.ncbi.nlm.nih.gov). Beyond bone, RANKL/RANK have roles in the immune system: human RANK mutations can cause hypogammaglobulinemia (impaired antibody production) due to effects on B-cell maturation (pmc.ncbi.nlm.nih.gov). Thus, patients with RANK-L or RANK defects may present with combined osteopetrosis and immune deficiencies (failure to form lymph nodes and poor B-cell function), highlighting the pleiotropic roles of this pathway (pmc.ncbi.nlm.nih.gov).

• Signaling Adapters and Transcription Factors: Osteoclast differentiation and function are controlled by downstream signaling cascades, notably the NF-κB pathway and related factors. Mutations in these signaling proteins can also cause osteopetrosis. For example, TNF Receptor-Associated Factor 6 (TRAF6) is an adapter protein that transmits signals from RANK to NF-κB and other pathways in osteoclast precursors. Rare mutations in TRAF6 have been identified that impair osteoclastogenesis (pmc.ncbi.nlm.nih.gov). Similarly, NEMO (NF-κB Essential Modulator, gene IKBKG, HGNC:6031) is a regulatory subunit of the IκB kinase complex required for NF-κB activation; mutations in IKBKG cause an X-linked form of osteopetrosis with immunodeficiency and ectodermal dysplasia (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In these patients, RANK signaling is uncoupled due to NF-κB not activating, leading to failed osteoclast differentiation. Another example is RELA (HGNC:9955), encoding the p65 subunit of NF-κB – mutation here can likewise undermine RANKL signaling and osteoclast formation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Downstream of RANK–NFκB, the master transcription factor for osteoclast lineage commitment is NFATc1 (activated by RANKL via NF-κB and calcium signals). While no human NFATC1 mutations are yet known in osteopetrosis, a transcription factor called MITF (HGNC:7114, Microphthalmia-associated TF) is critical for osteoclast gene expression and acts in parallel with NFATc1. Mutations in MITF cause a syndrome combining osteopetrosis with albinism, deafness, and eye defects (COMMAD syndrome) (pmc.ncbi.nlm.nih.gov). MITF is normally activated during osteoclast differentiation; loss of MITF impairs expression of osteoclast genes (including those for lysosomal enzymes), explaining the osteopetrotic phenotype (pmc.ncbi.nlm.nih.gov). These signaling and transcriptional regulators illustrate that disruption of osteoclastogenic signaling at various levels (cell surface receptor, adapter, transcription factor) can converge on the same outcome: blocked osteoclast formation.

• Cytoskeletal and Adhesion Proteins: Osteoclasts require a specialized actin cytoskeleton to form the sealing zone and ruffled border for bone resorption. Genes encoding proteins for osteoclast adhesion and cytoskeletal arrangement are also key. Kindlin-3 (FERMT3, HGNC:14566) is a cytoskeletal adaptor in integrin signaling, expressed in hematopoietic cells. It links integrins to the actin cytoskeleton. Loss of Kindlin-3 (known in humans as LAD-III syndrome) not only causes immunodeficiency and bleeding (due to leukocyte and platelet integrin dysfunction) but also osteopetrosis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Kindlin-3–deficient osteoclasts cannot properly attach to bone, failing to form the tight sealing zone needed for resorption (pmc.ncbi.nlm.nih.gov). This results in osteoclasts that are present but ineffective (“osteoclast-rich osteopetrosis” with a podosome/adhesion defect). Another such gene is ITGB3 (HGNC:6156), encoding the β3 integrin subunit (part of the vitronectin receptor α_vβ_3 used by osteoclasts to bind bone matrix). Though primarily known for causing Glanzmann thrombasthenia (a platelet aggregation disorder), β3 integrin mutations in mice cause osteopetrosis due to inability of osteoclasts to bind bone; similar phenomena likely occur in humans (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). CalDAG-GEF1 (gene RASGRP2, sometimes called Calcium and DAG-regulated guanine nucleotide exchange factor I*) is another protein that activates integrins; mutation in RASGRP2 has been reported to cause osteopetrosis with immune defects by preventing integrin activation on osteoclasts and leukocytes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Additionally, the gene LRRK1 (HGNC:18619, Leucine-Rich Repeat Kinase 1) has emerged as a player in osteoclast cytoskeletal dynamics. LRRK1 is a large signaling kinase that interacts with c-Src and other pathways to regulate the actin cytoskeleton and ruffled border formation (pmc.ncbi.nlm.nih.gov). Rare biallelic mutations in LRRK1 cause an autosomal recessive osteopetrosis variant called osteosclerotic metaphyseal dysplasia, characterized by metaphyseal sclerosis and fractures in childhood (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Osteoclasts lacking LRRK1 are abnormally large and flat, unable to properly reorganize their cytoskeleton or form resorption pits (pmc.ncbi.nlm.nih.gov). These examples underscore that osteoclast attachment and polarized resorption** depend on an intact cytoskeletal apparatus; genetic defects in those structural proteins can thus produce osteopetrosis even if the acid/enzyme machinery is intact.

• Colony-Stimulating Factor 1 (CSF1) Pathway: Osteoclasts derive from monocyte precursors whose survival and proliferation depend on M-CSF (macrophage colony-stimulating factor) signaling via its receptor CSF1R. Rare mutations in CSF1R (HGNC:2433) have been found in osteopetrotic individuals (and Csf1 knockout in mice – the “op/op” osteopetrotic mouse – demonstrates this pathway’s importance) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). When M-CSF signaling is absent, the pool of osteoclast precursors is greatly reduced, resulting in osteoclast-poor osteopetrosis. In humans, CSF1R mutations can cause an osteopetrosis with concurrent immune defects (since mononuclear phagocytes broadly require CSF1R).

Overall, the key molecular players in osteopetrosis are the genes that ensure osteoclasts form correctly, adhere to bone, acidify the resorption space, and secrete degradative enzymes. Mutations in any of these players – from extrinsic differentiation factors (RANKL/M-CSF) to osteoclast-intrinsic proteins (proton pumps, ion transporters, enzymes, signaling molecules, adhesion factors) – can lead to the final common outcome of deficient bone resorption. To date, 23 genes have been implicated in osteopetrosis or related high-bone-mass disorders (pmc.ncbi.nlm.nih.gov), reflecting significant progress in the molecular genetics of this disease. Major examples include TCIRG1, CLCN7, OSTM1, SNX10, PLEKHM1, CA2, TNFSF11 (RANKL), TNFRSF11A (RANK), CSF1R, IKBKG (NEMO), TRAF6, FERMT3 (Kindlin-3), LRRK1, MITF, RAG1/2, RASGRP2, CTSK, among others (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Each gene’s protein product plays a role in osteoclast formation or function, and their disruption illustrates the multiple biological pathways converging on the osteopetrotic phenotype.

3. Disrupted Biological Processes

Given the diverse genes involved, osteopetrosis can be viewed as a disorder of several converging biological processes related to bone resorption. Key Gene Ontology (GO) categories of processes disrupted in osteopetrosis include:

• Bone Resorption and Remodeling: The fundamental process affected is osteoclast-mediated bone resorption (GO:0045453). Normal bone remodeling is a coupled process; in osteopetrosis the resorptive phase fails. Processes like extracellular matrix catabolic process (degradation of collagen and mineral, GO:0030198) are impaired. The dissolution of bone mineral is halted due to failure of proton transport (GO:0016092) into the resorption lacuna. As a result, the bone remodeling cycle (GO:0046849) is skewed towards formation without resorption (pmc.ncbi.nlm.nih.gov). This manifests as continuous accumulation of bone mass without the usual turnover.

• Osteoclast Differentiation and Cell Fusion: Several osteopetrosis genes disrupt the osteoclast differentiation process (GO:0030278) from monocytes. For example, loss of RANKL/RANK signaling interrupts the differentiation sequence, preventing the formation of multinucleated osteoclasts (pmc.ncbi.nlm.nih.gov). Part of this process is cell-cell fusion of osteoclast precursors (GO:0006939) to form giant multinucleated cells – mutations in TNFSF11, TNFRSF11A, or CSF1R all halt this process, resulting in too few or no osteoclasts (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Transcriptional processes like activation of NF-κB signaling (GO:0051092) and NFAT import that drive osteoclast gene expression are also disrupted when signaling adapters or transcription factors (NEMO, TRAF6, MITF) are mutated (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Thus the normal biological program of monocyte → pre-osteoclast → active osteoclast is blocked.

• Proton Transport and pH Homeostasis: Osteoclast function relies on creating an acidic microenvironment. Biological processes such as vacuolar acidification and transmembrane proton transport (GO:0015992) are essential for bone resorption. Mutations in TCIRG1, CLCN7, OSTM1, CA2 all affect the process of acid secretion into the resorption lacuna (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Normally, osteoclasts pump H^+ ions out of the cytoplasm in exchange for cytosolic HCO_3^- (produced by carbonic anhydrase); this requires coordinated membrane transport of protons and counter-ions. Osteopetrotic osteoclasts often fail to maintain the low pH needed to dissolve mineral, so the process “bone mineral solubilization” is disrupted (pmc.ncbi.nlm.nih.gov). In GO terms, regulation of intracellular pH and lysosomal lumen acidification are pertinent processes perturbed by these gene defects.

• Ion Transport and Homeostasis: Alongside protons, chloride ion transport (GO:0006821) is a crucial process in osteoclasts. ClC-7 and OSTM1 normally facilitate Cl^- movement to balance charges during H^+ pumping (pmc.ncbi.nlm.nih.gov). Osteopetrosis due to CLCN7/OSTM1 thus represents a defect in anion transport affecting organelle and extracellular pH. Additionally, bicarbonate transport (to extrude the base produced by carbonic anhydrase) and calcium/phosphate handling (as bone minerals are released) are indirectly disrupted – for example, hypocalcemia can result if bone calcium is not mobilized and GI absorption is impaired. Indeed, calcium homeostasis processes can be affected, as seen in patients with TCIRG1 mutations who develop low serum Ca^2+ and secondary rickets (pmc.ncbi.nlm.nih.gov).

• Vesicle-Mediated Transport: Osteoclast activity involves intense vesicular trafficking – delivering proton pumps and enzymes to the ruffled border and endocytosing bone degradation products. Processes such as lysosomal vesicle fusion with plasma membrane (a form of exocytosis, GO:0000772) are critical. Genes like SNX10 and PLEKHM1 highlight disruption in endosome to plasma membrane transport and secretory lysosome organization (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In osteopetrosis due to SNX10 or PLEKHM1, the process of enzyme secretion (like that of MMP9, cathepsin K) is perturbed, meaning bone matrix is not degraded properly (pmc.ncbi.nlm.nih.gov). Therefore, GO processes such as protein targeting to membrane and vesicle-mediated protein transport are relevantly disturbed.

• Cytoskeletal Organization and Cell Adhesion: Osteoclasts must organize an actin-rich sealing zone; this involves actin cytoskeleton organization (GO:0030036) and focal adhesion assembly. Mutations in FERMT3 (Kindlin-3), ITGB3, and others impair the biological process of cell-matrix adhesion (GO:0007160) specific to osteoclasts attaching to bone (pmc.ncbi.nlm.nih.gov). Without a proper sealing zone, the acidic resorption compartment cannot form. Also, podosome assembly (specialized adhesion structures in osteoclasts) and ruffled border formation are processes requiring coordination of actin fibers, microtubules, and vesicle fusion (pmc.ncbi.nlm.nih.gov). LRRK1 mutation, for example, disrupts the process of cytoskeletal rearrangement during osteoclast activation (pmc.ncbi.nlm.nih.gov). Thus, osteopetrosis encompasses defects in these dynamic cellular processes: cell polarization, cytoskeletal reorganization, and matrix adhesion.

In summary, osteopetrosis spans a spectrum of biological process failures all ultimately leading to deficient bone resorption. From signal transduction (RANKL/RANK pathway) to cell differentiation, from ion transport and acid secretion to enzyme-mediated matrix catabolism, and from cell adhesion to multinuclear cell fusion, multiple GO-defined processes are perturbed. The unifying theme is that normal bone degradation processes are shut down, explaining the accumulation of bone and the downstream pathophysiological changes.

4. Key Cellular Components and Locations

At the cellular level, osteopetrosis implicates several critical cellular components and anatomical sites where the pathology unfolds:

• Osteoclast and its Subcellular Domains: The primary cell type affected is the osteoclast (bone-resorbing multinucleated giant cell, CL:0000092). Within the osteoclast, the most crucial structure is the ruffled border – a specialized folded plasma membrane domain that forms at the bone attachment site. The ruffled border is essentially the osteoclast’s secretory apparatus for bone resorption, analogous to an “extracellular lysosome.” It contains a high density of vacuolar H^+-ATPase pumps and ClC-7 chloride channels, which work together to acidify the enclosed space between osteoclast and bone (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In healthy osteoclasts, the ruffled border is where protons and proteases (e.g., cathepsin K) are released into the resorption lacuna (the extracellular compartment directly adjacent to the ruffled border). In osteopetrosis, this resorption lacuna (a critical extracellular space) is either not properly acidified or not properly formed. Electron microscopy of osteopetrotic osteoclasts often shows an absence of ruffled border or a poorly developed one (pmc.ncbi.nlm.nih.gov). Key cellular components here include the actin-rich sealing zone (also called the clear zone) which is a ring of F-actin structures that tightly seals the perimeter of the resorption lacuna to confine acid – mutations in kindlin-3 or integrins disrupt this structure (pmc.ncbi.nlm.nih.gov). The podosomes (integrin-containing adhesion complexes in that sealing zone) fail to mature without those cytoskeletal proteins, preventing effective bone attachment (pmc.ncbi.nlm.nih.gov). Also important are microtubules and vesicles in the osteoclast: proton pumps and enzymes are delivered via late endosomes/lysosomes that fuse with the ruffled border membrane (pmc.ncbi.nlm.nih.gov). In cases like SNX10 or PLEKHM1 mutations, mis-sorting of vesicles means V-ATPases remain trapped in the cytosol or mislocalized to the wrong membrane, underscoring how intracellular organelles (endosomes, lysosomes, Golgi) play a role in forming the resorption apparatus (pmc.ncbi.nlm.nih.gov). In summary, the osteoclast’s plasma membrane domain (ruffled border), its cytoskeletal attachments (sealing zone), and its acidic vesicular organelles (lysosomes) are key cellular components impacted in osteopetrosis.

• Bone Matrix and Extracellular Space: The disease pathology manifests in the bone tissue (UBERON:0002481) itself, particularly the extracellular matrix of bone which includes the inorganic mineral (hydroxyapatite) and organic matrix (collagen fibers). The hydroxyapatite crystals normally reside in the bone’s extracellular space and require acidic dissolution. In osteopetrosis, because the extracellular resorption space (lacuna) pH isn’t lowered effectively, these crystals remain in place, and the bone’s extracellular compartment accumulates excess mineral (pmc.ncbi.nlm.nih.gov). The anatomical locations most affected include the long bones, spine, and skull – essentially the entire skeleton exhibits high bone density, but certain sites lead to specific complications. For instance, the foramina in the skull base (through which cranial nerves pass) are encased by bone; when that bone overgrows and fails to remodel, the foramina narrow. This leads to compression of nerves (optic nerves in the optic canal, auditory nerves in internal acoustic meatus, etc.) – a direct result of pathology at those anatomical compartments. Another component is the bone marrow cavity (medullary cavity, UBERON:0002371): in healthy individuals, osteoclasts help hollow out the diaphyses of long bones to form marrow space. In osteopetrosis, the marrow cavity is filled with bone due to lack of osteoclastic excavation (pmc.ncbi.nlm.nih.gov). This anatomic failure underlies the hematological manifestations. Thus, the spatial context of osteopetrosis is the hard tissue of the skeleton, but its consequences extend to hematopoietic niches (marrow) and sites like cranial nerve canals and paranasal sinuses (leading to, e.g., choanal narrowing) (pmc.ncbi.nlm.nih.gov).

• Cells of the Monocyte Lineage: Beyond the osteoclast itself, its precursors – monocytes and macrophage-lineage cells (CL:0000576) – are also key cellular players. Osteoclasts derive from hematopoietic stem cells (HSCs in bone marrow), specifically from CFU-GM (colony-forming unit granulocyte-macrophage) progenitors under the influence of M-CSF and RANKL. In osteopetrosis forms caused by failure of differentiation signals (RANKL/RANK, CSF1R), the osteoclast precursor cells either fail to proliferate or to differentiate/fuse. These precursors might accumulate or, conversely, undergo apoptosis if they cannot become functional osteoclasts. For example, in RANKL or RANK deficiency, monocytes cannot acquire an osteoclast identity, leading to osteoclast absence in bone but potentially accumulation of undifferentiated monocytes elsewhere (pmc.ncbi.nlm.nih.gov). This interplay is relevant when treating osteopetrosis: hematopoietic stem cell transplantation (HSCT) introduces donor HSCs that give rise to functional osteoclast-lineage cells, effectively replacing the patient’s defective osteoclasts (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The success of HSCT in osteopetrosis underscores that the bone-resorbing cells are of hematopoietic origin, and replacing that cellular component can cure the bone pathology (provided the genetic defect is in those cells and not in the bone microenvironment).

• Other Tissues/Cells Affected: While osteoclasts are the central cells, the disease’s effects involve other cell types secondarily. Osteoblasts (bone-forming cells) are generally normal in osteopetrosis, but the lack of coupling with resorption can alter their behavior. In some reports, high bone mass signals can downregulate osteoblast activity or change bone formation patterns. Also, chondroclasts (cartilage-resorbing cells, essentially osteoclasts acting on growth plate cartilage) may be affected – leading to failure to remodel primary spongiosa in the growth plate and flared metaphyses. This is observed as an ends-of-bones abnormality (Erlenmeyer flask deformity on X-ray). The immune cells are another cellular component: because many osteopetrosis genes play roles in immune function (e.g., RANK/RANKL in lymph node development, kindlin-3 in leukocyte integrins, RAG1/2 in lymphocyte development, NEMO in NF-κB immune signaling), patients often have immune system involvement. For example, T and B lymphocytes may be normal in classic osteopetrosis, but in the RANKL/RANK deficient forms, patients can have few lymph nodes and poor B-cell antibody production (pmc.ncbi.nlm.nih.gov); in IKBKG (NEMO) mutations, there is immunodeficiency (typically NEMO syndrome causes susceptibility to infections) in addition to bone sclerosis (pmc.ncbi.nlm.nih.gov). Furthermore, renal tubular cells can be indirectly involved in CAII-deficient osteopetrosis, as carbonic anhydrase II is needed in renal tubules for acid secretion – hence those patients have renal tubular acidosis as a systemic complication (the kidney being an anatomical site of pathology due to the same enzyme defect). Lastly, neuronal cells: OSTM1 is expressed in neurons and oligodendrocytes; thus OSTM1-mutant osteopetrosis shows primary neurodegeneration (seizures, cerebral atrophy) beyond just nerve compression (pmc.ncbi.nlm.nih.gov). This reminds us that certain osteopetrosis genes have roles in cells outside the bone, and their loss leads to multi-system pathology.

In essence, the key cellular components of osteopetrosis center on the osteoclast and its bone-resorbing apparatus – the ruffled border, sealing zone, and acidic vesicles – along with the bone extracellular matrix which is the substrate of the disease. The anatomical context is the entire skeleton, especially trabecular bone regions and sites needing remodeling. By understanding which cellular compartments (lysosome, plasma membrane, actin cytoskeleton) and anatomical structures (bone marrow cavity, cranial foramina) are involved, we see how a molecular defect inside an osteoclast leads to system-wide effects.

5. Disease Progression and Pathogenic Sequence

Osteopetrosis often begins in utero and progresses through distinct phases depending on severity. The initiating event is a germline mutation in one of the osteoclast-essential genes described. This genetic lesion is present from conception, meaning that from the earliest stages of skeletal development the normal bone remodeling processes are altered.

In severe (malignant) autosomal recessive osteopetrosis (ARO), the disease process is active during fetal bone formation. Normally, as the fetus’s bones ossify, osteoclasts remove transient cartilage and open up the medullary cavities. In osteopetrosis, failure of fetal osteoclast activity leads to bones that retain their primitive structure – for example, the fetal metaphyses contain unresorbed cartilage. The newborn may have diffusely dense bones on prenatal or neonatal imaging. Soon after birth, the consequences of marrow cavity obliteration appear: the infant develops cytopenias as bone marrow failure sets in (often in the first weeks to months of life) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The inability to produce blood cells leads to anemia and thrombocytopenia, typically noticed within the first 6 months of life as the maternal blood supply and fetal stores wane. At the same time, extramedullary hematopoiesis ramps up to compensate – the infant’s liver and spleen enlarge (hepatosplenomegaly) as they attempt to make blood cells outside the marrow (pmc.ncbi.nlm.nih.gov). This marks a second phase: hematologic and visceral complications become evident. Infants can present with failure to thrive, recurrent infections, and extramedullary hematopoietic masses.

Another early event in severe ARO is the effect on calcium metabolism. Since bone resorption is a key source of circulating calcium (especially during periods of rapid growth), many infants with osteopetrosis develop hypocalcemia. In classic malignant osteopetrosis, serum calcium may drop low enough to cause tetanic seizures in infancy (pmc.ncbi.nlm.nih.gov). This is exacerbated in TCIRG1-related cases by concomitant stomach achlorhydria reducing calcium absorption (pmc.ncbi.nlm.nih.gov). Thus, metabolic disturbances like hypocalcemia emerge early, sometimes with irritability or seizures being a presenting sign.

As the infant grows, skeletal changes progress. The skull bones continue to thicken (since osteoblasts still lay down bone for growth, but osteoclasts do not remodel it). Within the first year of life, many untreated ARO patients develop macrocephaly with frontal bossing and a characteristic craniofacial appearance (pmc.ncbi.nlm.nih.gov). The enlarging skull can cause narrowing of cranial nerve foramina. Typically, optic nerve compression presents in infancy or early childhood – parents may notice loss of visual tracking or nystagmus as the optic nerves are pinched in narrowed optic canals. Auditory nerve compression can lead to hearing loss. Facial nerve palsy or trigeminal nerve symptoms can also occur, though blindness is most common. Another potential complication in infancy is hydrocephalus; thickening at the skull base can impede cerebrospinal fluid outflow or constrict the jugular foramina, leading to intracranial pressure increase (pmc.ncbi.nlm.nih.gov). The long bones in infants with ARO often show Erlenmeyer flask deformity (flared metaphyses) because modeling (shaping of bone ends) is deficient. By toddler age, untreated malignant osteopetrosis leads to profound developmental delay, partly from anemia/hypoxia and partly from neurologic impairment (optic nerve damage causing blindness, etc.). Most infants with malignant ARO suffer life-threatening complications (severe infections due to leukopenia or bleeding from thrombocytopenia) and if untreated, many die in infancy or early childhood (pmc.ncbi.nlm.nih.gov). Historical data indicated that without treatment, many children succumb by age 3–4 from anemia or infection. With modern supportive care (transfusions, antibiotics) some may survive a bit longer, but the disease is typically fatal in the first decade unless HSCT is performed (pmc.ncbi.nlm.nih.gov).

If a hematopoietic stem cell transplant (HSCT) is performed early (e.g. before 1 year of age in malignant ARO), the disease course can dramatically change. Donor-derived osteoclasts begin to populate the bones and gradually restore bone resorption. Over months to years post-transplant, bone density can decrease towards normal, marrow space can reopen (allowing blood counts to recover), and further neurodegeneration can be halted (though existing nerve damage may be irreversible) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Thus, HSCT essentially resets the disease progression by addressing the root cause (lack of functional osteoclasts).

In intermediate autosomal recessive osteopetrosis, the sequence is similar but slower. These patients (often with CA2 or PLEKHM1 mutations, etc.) might have a marrow that functions at birth and during early childhood but gradually becomes insuffient. They may not present in infancy, but instead during the first decade of life with symptoms like growth failure, frequent fractures, or anemia developing later (www.ncbi.nlm.nih.gov). They often have pathologic bone fractures once they start ambulating – the brittle bones can fracture with minimal trauma (e.g., a toddler presenting with a femur fracture). Cranial nerve compression can also develop over time, perhaps in late childhood, leading to gradual vision or hearing impairment. Compared to malignant ARO, these intermediate forms show a protracted progression: patients often survive into adolescence or adulthood even without transplant, though with morbidity such as repeated fractures, bone deformities, and nerve deficits (www.ncbi.nlm.nih.gov). For example, some intermediate cases might not lose vision until teenage years if the optic canals narrow slowly. They may also suffer from mandibular osteomyelitis in childhood, especially after tooth extractions (dense bone with poor vascularity predisposes to infection). The need for intervention is determined by symptoms; some intermediate patients have been managed conservatively or with therapies like interferon-γ (which can modestly activate osteoclasts – see below) as a bridge to possible transplant (pmc.ncbi.nlm.nih.gov).

In autosomal dominant (adult) osteopetrosis (ADO), the disease progression is usually much milder and later in onset. There are two main ADO subtypes (often called Type I and Type II). ADO Type II (Albers-Schönberg disease, usually due to CLCN7 heterozygous mutations) often is asymptomatic through childhood and is discovered in late adolescence or adulthood, sometimes incidentally via X-ray (www.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). If symptoms occur, they typically begin in the 3rd to 4th decade of life. The progression features recurrent fractures (particularly of long bones or compressive fractures in spine), early onset osteoarthritis or degenerative joint disease (due to abnormal bone remodeling around joints), and dental issues (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Cranial nerve compression is relatively rare in ADO (only ~5% have vision/hearing loss) (pmc.ncbi.nlm.nih.gov), owing to the more moderate sclerosis. However, osteomyelitis of the jaw is a classic complication in adult osteopetrosis: middle-aged patients might develop refractory mandibular osteomyelitis after a dental infection, due to poor blood supply in sclerotic bone (pmc.ncbi.nlm.nih.gov). ADO Type I (less common, sometimes not linked to CLCN7) might present with diffuse cranial vault sclerosis but minimal symptoms. Overall, life expectancy in adult forms is normal (pmc.ncbi.nlm.nih.gov), and many individuals never realize they have osteopetrosis unless an X-ray for something else reveals it. The disease progression in these cases is so slow that it might be considered a static osteosclerosis rather than a progressive condition – though microdamage accumulation can still lead to problems like fractures or arthritis in later life.

Importantly, the progression can vary with genotype. For example, RANKL-deficient patients reportedly have a somewhat slower progression of osteopetrosis than TCIRG1-deficient patients (pmc.ncbi.nlm.nih.gov). OSTM1 and certain CLCN7 mutations cause early and severe neurological decline (developmental regression, seizures) in infancy – a progression driven by primary neuronal degeneration in parallel to bone disease (pmc.ncbi.nlm.nih.gov). These patients often do not survive beyond age 2–3 even with transplant, because the neurological component is not rescued by HSCT. Thus, one can consider osteopetrosis progression as having subtypes: a purely skeletal progression (vision loss, fractures, marrow failure) versus a multisystem progression (if the gene impacts brain, immune system, etc.). Table-based classifications exist separating “malignant,” “intermediate,” “adult benign,” and “variant” forms (www.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) – each with its typical timeline and organ involvement.

To summarize disease course: Initial trigger – a genetic mutation impairing osteoclast function from conception. Early events – failure of bone remodeling during growth, leading to high bone mass and narrowed marrow space visible by birth or infancy; onset of cytopenias, hypocalcemia, and cranial nerve entrapment in severe cases within months. Progression – accumulation of bone and loss of marrow continue, causing fractures (with minimal trauma) and progressive skeletal deformity, with systemic complications (pancytopenia, extramedullary hematopoiesis, growth failure). Advanced disease – in severe untreated cases, ends with bone marrow failure complications or neurological devastation in early childhood; in milder cases, leads to orthopedic issues and some disability in adulthood. Intervention (HSCT) early can arrest or reverse the course by restoring osteoclast activity, fundamentally altering the progression to a more benign outcome if successful.

6. Phenotypic Manifestations and Clinical Correlation

The clinical phenotype of osteopetrosis is directly related to its pathophysiology. The hallmark phenotype is increased bone density on radiographs (diffuse osteosclerosis). Paradoxically, patients suffer from bone fragility – pathological fractures are common. Below are key phenotypic features and their mechanistic basis:

• Generalized Osteosclerosis (High Bone Density): On X-ray, virtually all bones appear abnormally dense (HP:0004348, “increased bone density”). Long bones have dense diaphyses with “bone-in-bone” appearance (endobones) due to retention of primary trabeculae. Vertebrae show “sandwich vertebra” or “rugger-jersey spine” patterns (dense endplates). The skull is thickened, sometimes obliterating the diploic space. This radiographic dense bone corresponds to excessive mineralized matrix left unresorbed (www.ncbi.nlm.nih.gov). Clinically, the patient may have a heavy, broad forehead (frontal bossing) and palpable bone thickening. Macrocephaly is often noted in infants (HP:0000256), resulting from unrestrained calvarial bone growth without inner table resorption (pmc.ncbi.nlm.nih.gov). In adults, dense bones are often found incidentally; in children, x-rays taken for fractures reveal the sclerosis.

• Bone Fragility and Fractures: Despite high bone mass, the bone quality is poor. Patients experience frequent fractures (HP:0002757, pathologic fractures). The mechanism is that the osteosclerotic bone is brittle – it lacks the normal microarchitecture and contains persistent calcified cartilage (making it less tough) (www.ncbi.nlm.nih.gov). Additionally, because remodeling is suppressed, microdamage accumulates. Long bone fractures (femur, tibia) are common, often with minimal trauma (e.g., a toddler stands and their femur fractures). In adult ADO, fractures of the femur or tibia may occur during normal activities. Fracture healing can also be impaired or delayed (since osteoclasts help in callus remodeling); non-union or malunion of fractures is a complication (pmc.ncbi.nlm.nih.gov). This fragility despite sclerosis is a classic clinical paradox explained by the pathophysiology (“too much bone, but of poor quality”).

• Bone Marrow Failure (Pancytopenia): A life-threatening phenotype in severe osteopetrosis is pancytopenia (HP:0002128) – anemia, thrombocytopenia, and leukopenia. The root cause is replacement of marrow space by bone (pmc.ncbi.nlm.nih.gov). Infants present with anemia (HP:0001903) causing pallor and fatigue, thrombocytopenia (HP:0001873) causing bruising or bleeding, and leukopenia leading to recurrent infections. Laboratory tests show low blood counts, and bone marrow biopsy (if performed) is often “dry” or shows myeloid cells squeezed in narrow spaces. Clinically this can manifest as failure to thrive (due to anemia and increased work of breathing), frequent infections (often pneumonia or sepsis from neutropenia), and petechial rashes or serious bleeding (from low platelets). The liver and spleen enlargement (hepatosplenomegaly, HP:0001433) is directly related: because marrow production is insufficient, extramedullary hematopoiesis occurs in these organs (pmc.ncbi.nlm.nih.gov). Parents may notice a swollen abdomen in the infant due to massive hepatosplenomegaly. This phenotype ties back to marrow space obliteration – once again showing how lack of osteoclast-mediated cavity formation leads to hematologic disease.

• Cranial Nerve Compression and Neurologic Signs: Thickening of bones at the skull base and around foramina leads to several neurologic phenotypes. Optic nerve compression causes optic atrophy and vision loss (HP:0000648). In an infant or child, this might present as loss of visual tracking, nystagmus, or blindness. Auditory nerve compression can cause sensorineural hearing loss (HP:0000407). Facial nerve palsy (facial paralysis, HP:0007209) or trigeminal nerve impairment (facial numbness) are less common but can occur. Some patients develop hydrocephalus (HP:0000238) manifesting as irritability, vomiting, and a bulging fontanelle in infants, due to narrowed jugular foramina or decreased CSF outflow (pmc.ncbi.nlm.nih.gov). Mechanistically, these neurological phenotypes result from bone overgrowth in confined spaces – a direct outcome of uncontrolled bone deposition. Additionally, in the “neurropathic” forms of osteopetrosis (like OSTM1 mutation), there are primary brain abnormalities: these infants can have seizures and developmental regression independent of nerve compression, due to intrinsic CNS degeneration (pmc.ncbi.nlm.nih.gov). For example, retinal degeneration and early-onset seizures in OSTM1-related osteopetrosis reflect OSTM1’s role in neurons and are part of the phenotype (the term “optic atrophy” can result both from nerve compression and retinal degeneration in such cases) (pmc.ncbi.nlm.nih.gov). In summary, vision and hearing loss (occurring in a significant fraction of severe cases, and ~5% of adult cases (pmc.ncbi.nlm.nih.gov)) and other cranial neuropathies are key phenotypic manifestations tied to bone encroachment on neural structures.

• Growth Impairment and Deformities: Many patients with malignant osteopetrosis exhibit short stature (HP:0004322 or generalized growth failure). This can result from several factors: intrinsic bone growth abnormality (impaired remodeling of growth plates), chronic illness/malnutrition, and anemia. Radiologically, long bones often show abnormal modeling: Erlenmeyer flask deformity (flaring of the metaphyses) and undertubulation of shafts. The craniofacial bones enlarge abnormally, leading to characteristic facies (frontal bossing, hypertelorism due to broad skull, and macrocephaly). Dental deformities are also part of the phenotype: children often have delayed or failed tooth eruption (HP:0006288) because osteoclasts normally resorb bone to create an eruption path for teeth (pmc.ncbi.nlm.nih.gov). As a result, patients may have retained deciduous teeth, or teeth that never emerge, leading to dental crowding. When teeth do erupt, the dense bone and altered immune environment predispose to dental caries and abscesses. This is dangerous because osteomyelitis of the jaw (usually mandible) is a noted complication – even a small dental infection can spread in the poorly vascularized sclerotic bone, causing a chronic refractory osteomyelitis (pmc.ncbi.nlm.nih.gov). Clinicians treating osteopetrosis patients are cautious with dental extractions and often give antibiotic prophylaxis because of this risk.

• Hypocalcemia and Rickets: As mentioned, severe infantile osteopetrosis can cause hypocalcemia (HP:0002901), which sometimes leads to tetany or seizures. This might seem counterintuitive since bones hold excess calcium, but the lack of bone turnover means calcium is “locked” in bone and not released into blood. In addition, children may develop a form of rickets/osteomalacia on top of osteopetrosis. For example,TCIRG1-associated osteopetrosis often shows rachitic changes (bowing of long bones, metaphyseal widening) because gastric acid absence impairs calcium absorption, compounding the hypocalcemia (pmc.ncbi.nlm.nih.gov). Thus, one sees a phenotype of bone sclerosis with superimposed rickets – the dense bones paradoxically have features of poor mineralization in growth plates due to systemic calcium/phosphate imbalance. Treating these patients requires calcium and vitamin D supplementation to manage the metabolic bone aspect (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

• Immune and Other Systemic Features: Certain genetic subtypes bring unique phenotypes. Combined immunodeficiency is seen in forms like RANKL/RANK deficiency and IKBKG (NEMO) mutations. Patients might have recurrent infections and fail to form lymph nodes (agammaglobulinemia, as noted with RANK mutations) (pmc.ncbi.nlm.nih.gov) or have ectodermal dysplasia signs (sparse hair, abnormal teeth/sweat glands in NEMO-related Disorder) alongside osteopetrosis (pmc.ncbi.nlm.nih.gov). Renal tubular acidosis is part of the phenotype for CAII deficiency, presenting as failure to thrive and metabolic acidosis in infancy (due to inability of kidneys to acidify urine). Cerebral calcifications (basal ganglia calcification) can also occur in CAII deficiency, reflecting chronic acidosis. Skin changes or hematological malignancies are not typical of osteopetrosis per se, but treatment with transplant carries a risk of graft-versus-host disease which can cause skin lesions.

A summary of the prototypical clinical manifestations would include: macrocephaly, frontal bossing, broad face; vision and hearing loss; dental abnormalities; growth retardation; anemia and hepatosplenomegaly; frequent fractures; skeletal deformities; and the radiographic hallmark of diffuse osteosclerosis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Each of these can be traced to the underlying cellular dysfunction. For example, pathologic fractures and deformities correspond to un-remodeled brittle bone; pancytopenia and hepatosplenomegaly correspond to loss of marrow space; nerve compressions correspond to bony encroachment; tooth eruption failure corresponds to lack of bone resorption in jaws; hypocalcemic seizures correspond to failure of osteoclasts to release calcium (and sometimes GI acid issues).

Clinicians often use clinical phenotypes to suspect the underlying gene: e.g., osteopetrosis + immunodeficiency suggests checking RANK/RANKL or Kindlin3; osteopetrosis + renal tubular acidosis → check CAII; osteopetrosis + skin/teeth defects → check IKBKG (NEMO); osteopetrosis + albinism → check MITF, etc. (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). But regardless of the specific combination, all patients share the core phenotype of excess bone that is structurally unsound.

Finally, it’s worth noting how understanding these phenotypes has guided therapy: recognizing that hematopoietic issues come from lack of osteoclasts led to the use of bone marrow transplantation to introduce functional osteoclasts (pmc.ncbi.nlm.nih.gov). Observing that interferon-γ can activate macrophages, clinicians tried Interferon-γ1b therapy in some patients, which showed modest improvement in bone resorption and blood counts (pmc.ncbi.nlm.nih.gov). High-dose calcitriol (active vitamin D) has been used to stimulate dormant osteoclasts (by inducing RANKL expression and osteoclast activity), sometimes alongside a low-calcium diet to provoke parathyroid hormone release – an attempt to pharmacologically tip the balance toward resorption (pmc.ncbi.nlm.nih.gov). These interventions derive from a deep understanding of the osteoclast biology underlying the phenotype.

In conclusion, the phenotype of osteopetrosis – marble bones that fracture, anemia with extramedullary hematopoiesis, cranial nerve palsies, and metabolic disturbances – can be directly correlated with the molecular derangements in osteoclasts. Each clinical feature is a consequence of failed cellular processes in bone resorption, underscoring how crucial osteoclasts are for both skeletal and systemic homeostasis.

References: (Key evidence is drawn from primary literature and reviews: Nadyrshina et al., 2023 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov); Stark & Savarirayan, 2009 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov); Sobacchi et al., 2013; Funck-Brentano et al., 2024; among others, as cited above.) Each citation corresponds to peer-reviewed sources that detail the genetic causes, molecular mechanisms, and clinical aspects of osteopetrosis. The pathophysiological understanding presented here is current as of 2024, reflecting over a decade of research that expanded the known gene list from 10 to 20+ genes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) and introduced new therapeutic considerations. This comprehensive view integrates recent findings (e.g., novel genes like LRRK1 (pmc.ncbi.nlm.nih.gov), FERMT3 (pmc.ncbi.nlm.nih.gov), TNFRSF11A/RANK causing immunodeficiency (pmc.ncbi.nlm.nih.gov)) with classic knowledge of osteoclast biology, providing a detailed picture of osteopetrosis pathophysiology backed by current, authoritative evidence.